Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
In memoriam: Kevin Dunbar, who traced the neural basis of human reasoning
Using imaging technologies, he transformed our understanding of how creativity and scientific discovery arise in the brain.
In memoriam: Kevin Dunbar, who traced the neural basis of human reasoning
Using imaging technologies, he transformed our understanding of how creativity and scientific discovery arise in the brain.
Neurons engage in risky, DNA-breaking business during migration
The cells later repair the damage, which occurs mostly in transcriptionally silent parts of the genome.
Neurons engage in risky, DNA-breaking business during migration
The cells later repair the damage, which occurs mostly in transcriptionally silent parts of the genome.
Study questions DSM-5’s combining of autism traits
Sensory traits and restricted and repetitive behaviors are best understood as distinct but related characteristics, the new work suggests.
Study questions DSM-5’s combining of autism traits
Sensory traits and restricted and repetitive behaviors are best understood as distinct but related characteristics, the new work suggests.